Objective To investigate the effects of Rituximab plus CHOP（R-CHOP）on programmed cell death protein 1（PD-1）

programmed death-ligand 1（PD-L1）

T cell subsets and natural killer cells（NK cells）in patients with diffuse large B-cell lymphoma（DLBCL）.Methods Eighty patients with DLBCL who were treated in a hospital in Liaoning province from June 2018 to June 2019 were selected and divided into control group（n=40）and observation group（n=40）by random number table.Patients in the control group were treated with conventional CHOP

and observation group were given R-CHOP.The clinical efficacy

positive rates of PD-1 and PDL1

levels of T cell subsets and NK cells and incidence of adverse reactions were compared between the two groups after treatment.Results After treatment

the total effective rate was 80.0%in control group and 95.0%in observation group（P

<

0.05）.The positive rate of PD-1 was 70.0%in control group and 47.5%in observation group（P

<

0.05）.The positive rate of PD-L1 was 72.5%in control group and 50.0%in observation group（P

<

0.05）.Before treatment

there were no statistically significant difference in CD3

+

CD4

+

CD8

+

CD4

+

/CD8

+

and NK cells levels between 2 groups（P

>

0.05）.After treatment

the levels of CD3

+

CD4

+

CD8

+

CD4

+

/CD8

+

and NK cells were significantly increased in both groups（P

<

0.05）

and the changes were greater in observation group（P

<

0.05）.Conclusion R-CHOP chemotherapy has significant effects on DLBCL

and it can effectively improve the positive rate of PD-1 and PD-L1 and the level of T cell subsets and NK cells in patients

thus it is worthy of wider clinical application.